3
Announcements
Trials
Browse
Landscape
Status
Terminated
1
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
Fluorodeoxyglucose F18
3
pembrolizumab
2
sacituzumab govitecan
1
ibrutinib
1
erdafitinib
1
enzalutamide
1
enfortumab vedotin
1
dynorphin-converting endopeptidase
1
avelumab
1
apixaban
1
Vinblastine
1
Surveys and Questionnaires
1
Specimen Handling
1
Radiosurgery
1
Pancreatectomy
1
Paclitaxel
1
Nivolumab
1
Methotrexate
1
Magnetic Resonance Imaging
1
JNJ-64619178
1
JNJ-64264681
1
Inosine Monophosphate
1
Health Information Exchange
1
Genetic Testing
1
Genetic Counseling
1
Gemcitabine
1
Focus Groups
1
Enoxaparin
1
Docetaxel
1
Cystoscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Enrolling by invitation
×
Inosine Monophosphate
×
Genitourinary
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled